2. Gestational Diabetes Mellitus (GDM)
Overview
Affects 2 to 9 percent of all pregnancies.
Associated with maternal and perinatal complications.
Long-term adverse health outcomes among infants born to mothers
with GDM:
– Sustained impairment of glucose tolerance
– Subsequent obesity
– Impaired intellectual achievement
The risk of macrosomia is increased.
2 of 35 PBRC 2009
3. Gestational Diabetes (GDM)
Development
Related to increased maternal body mass index (BMI).
Pre-pregnancy BMI of 30 kg/m2 or higher is a strong risk factor for the
development of GDM.
Maternal obesity combined with an excessive weight gain during pregnancy
are major risk factors for:
– pre-eclampsia
– Cesarean section
– preterm delivery
– fetal macrosomia
– fetal death.
3 of 35 PBRC 2009
4. Macrosomia
An oversized fetus.
Occurs frequently in women with diabetes.
Can lead to trauma during birth and a greater
chance of a cesarean delivery.
4 of 35 PBRC 2009
5. Large for Gestational
Age babies
Birth weight above the
90th percentile, is
considered as LGA (large
for gestational age).
5 of 35 PBRC 2009
6. Around the World
Increasing proportion of infants born with a high birth weight (HBW).
In Sweden, HBW infants has risen to more than 20%.
A similar pattern occurs in North America and Europe.
Researchers have found that
– increasing maternal weight
– gestational weight gain
– gestational diabetes
– reduced smoking prevalence
among pregnant women may likely explain the increase in proportion of LGA
births between 1976 and 1996 in Canada.
6 of 35 PBRC 2009
7. Factors relating to LGA babies
Related to the level of glycemic control that
the mother achieves.
Other factors that contribute to the
development of LGA neonates are:
– Obesity of the mother
– Excessive weight gain in pregnancy
7 of 35 PBRC 2009
8. Research
Maternal diabetes
control on infant
health at birth and
in later life.
9. Fetal Growth Spurt and Pregestational
Diabetic Pregnancy
Researchers assessed the timing of the fetal growth spurt among
pre-existing diabetic pregnancies (types 1 and 2) and its
relationship with diabetic control.
They hoped to find correlations between fetal growth
acceleration and factors influencing this occurrence.
Wong S, Oats J, Chan F, McIntyre D. Diabetes Care. 2002; 25: 1681-1684
9 of 35 PBRC 2009
10. Fetal Growth Spurt and Pregestational
Diabetic Pregnancy
In this study of 101 diabetic pregnancies, glucose control was
found not to have a direct effect on the incidence of LGA
babies.
Instead, maternal BMI was shown to have the more direct
and greater effect.
Pregnancies were separated into two groups:
– Diabetic mothers with normal weight babies
– Diabetic mothers with LGA babies
Wong S, Oats J, Chan F, McIntyre D. Diabetes Care. 2002; 25: 1681-1684
10 of 35 PBRC 2009
11. Fetal Growth Spurt and Pregestational
Diabetic Pregnancy
The women of the group with LGA babies were
shown to have significantly higher pre-pregnancy
body weights and BMI’s.
There were no differences between the two
groups with glucose control in either the first,
second, or third trimester.
Wong S, Oats J, Chan F, McIntyre D. Diabetes Care. 2002; 25: 1681-1684
11 of 35 PBRC 2009
12. Conclusions
Fetal growth acceleration in LGA fetuses of diabetic mothers was shown to
begin in the second trimester, from as early as 18 weeks.
In this particular study, glucose control did not appear to have any direct
effect on the incidence of LGA babies, and such observation might result
from the effects of other not yet identified contributing factors.
Wong S, Oats J, Chan F, McIntyre D. Diabetes Care. 2002; 25: 1681-1684
12 of 35 PBRC 2009
13. Determinants of Fetal Growth at Different Periods of
Pregnancies Complicated by GDM or Impaired Glucose
Tolerance (IGT)
The aim of this study was to determine what maternal
factors had the strongest influence on fetal growth at
different periods of pregnancies complicated by an
abnormal glucose tolerance test (GTT).
The fetal abdominal circumference (AC) is used to describe
fetal growth in this study because accelerated growth in
the fetal AC in the early 3rd trimester has been shown to be
a good predictor of macrosomia at birth.
Schaefer-Graf U et al. Diabetes Care. 2003; 26: 193-198.
13 of 35 PBRC 2009
14. Determinants of Fetal Growth at Different
Periods of Pregnancies Complicated by GDM
or Impaired Glucose Tolerance (IGT)
Normalizing the macrosomia rate is the primary goal in treating women with
pregnancies complicated by GDM.
Macrosomia is not only associated with a higher rate of birth injury for the
mother and newborn, but it is also associated with higher weight and
accumulation of fat in childhood, with a higher rate of obesity in adulthood.
Although normalizing maternal glucose levels has reduced neonatal morbidity
in GDM, it has not been as effective in regards to macrosomia.
Macrosomia rates in mothers with GDM when compared to mothers without
GDM still remain elevated even with maternal glucose normalization.
Schaefer-Graf U et al. Diabetes Care. 2003; 26: 193-198.
14 of 35 PBRC 2009
15. Determinants of Fetal Growth at Different
Periods of Pregnancies Complicated by GDM
or Impaired Glucose Tolerance (IGT)
Because maternal weight, glycemia after therapy, rates of fetal
macrosomia, and LGA were not significantly different between GDM
and IGT groups, they were analyzed together.
Results indicated that in the late 2nd and early 3rd trimester,
maternal BMI and LGA in a previous pregnancy appear to have the
strongest influence on fetal growth.
Later in the 3rd trimester, coincident with the period of maximal growth
described in diabetic pregnancies, maternal glycemia predominates.
Schaefer-Graf U et al. Diabetes Care. 2003; 26: 193-198.
15 of 35 PBRC 2009
16. Conclusions
Conclusions of this second study were in agreement with the first, stating
that maternal BMI has a great effect on the development of LGA babies.
However, this study went a step further in finding that both maternal BMI
and LGA in a previous pregnancy had the largest influence on fetal growth,
and identified the time frame when this effect was predominant.
This study also found that maternal glycemia does effect fetal growth, and
found the particular time frame when its effects occurred.
Schaefer-Graf U et al. Diabetes Care. 2003; 26: 193-198.
16 of 35 PBRC 2009
17. What Degree of Maternal Metabolic Control in
Women With Type 1 DM is Associated with
Normal Size & Proportions in Full-Term Infants?
The aim of this study was to assess the degree of maternal metabolic
control in women with Type 1 DM necessary to allow for normal fetal
growth and normal neonatal body proportions.
In this study, the anthropometric characteristics of 98 full-term singleton
infants born to 98 Caucasian women with Type 1 DM were measured.
All women were enrolled within 12 weeks of gestation and were later placed
in one of three mother-infant pair groups based on the level of glycemic
control they were able to maintain over the 2nd and 3rd trimesters of
pregnancy.
Mello G et al. Diabetes Care. 2000; 23: 1494-1498.
17 of 35 PBRC 2009
18. What Degree of Maternal Metabolic Control in
Women With Type 1 DM is Associated with
Normal Size & Proportions in Full-Term Infants?
The three groups were:
Number of mother-infant pairs Criteria required to be a member
Group 1 37 An average daily glucose level during
the 2nd and 3rd trimester of ≤ 95 mg/dl
Group 2 37 An average daily glucose level during
the 2nd trimester of > 95 mg/dl and
during the 3rd trimester of ≤ 95 mg/dl
Group 3 24 An average daily glucose level during
the 2nd and 3rd trimester of > 95 mg/dl
There was a control group of 1,415 Caucasian mother-infant pairs with
full-term singleton pregnancies. Members of the control group had normal
glucose challenge test when screened for gestational diabetes.
18 of 35 PBRC 2009
Mello G et al. Diabetes Care. 2000; 23: 1494-1498.
19. What Degree of Maternal Metabolic Control in
Women With Type 1 DM is Associated with
Normal Size & Proportions in Full-Term Infants?
Infants of diabetic mothers in group 1 of this study were found to be
similar to those of the control group in birth weight and in other
anthropometric parameters.
In contrast, offspring of diabetic mothers of groups 2 and 3 had an
increased incidence of LGA, significantly greater means of ponderal index
and thoracic circumferences, and significantly smaller cranial/thoracic
circumference ratios with respect to the control group.
Mello G et al. Diabetes Care. 2000; 23: 1494-1498.
19 of 35 PBRC 2009
20. Conclusions
The results of the study indicate that, in diabetic pregnancies, only overall
daily glucose values of ≤ 95 mg/dl throughout the second and third
trimesters can avoid alterations in fetal growth.
Mello G et al. Diabetes Care. 2000; 23: 1494-1498.
20 of 35 PBRC 2009
21. Evaluation of Body Composition of LGA Infants
of Women with GDM compared with Women
with Normal Glucose Tolerance Levels
The purpose of this study was to determine whether or not there is a
difference in body composition in the LGA infants of women with GDM
compared with the LGA infants of women with normal glucose tolerance
levels.
The researchers also wanted to identify factors associated with the
different levels of fat mass in these infants if a difference in body
composition was found.
Durnwald C, Huston-Presley L, Amini S, Catalano P. Am J Obstet Gynecol 2004; 191: 804-8
21 of 35 PBRC 2009
22. Evaluation of Body Composition of LGA Infants
of Women with GDM compared with Women
with Normal Glucose Tolerance Levels
Fifty cases of women with gestational diabetes and 52 cases of women
with normal glucose tolerance levels were evaluated in the study.
Researchers found that infants born in the two groups did have similar
birth weights.
Infants born to mothers with gestational diabetes did, in fact, have
increased fat mass and percent body fat, with decreased lean body mass,
when compared to infants of mothers with normal glucose tolerance levels.
Durnwald C, Huston-Presley L, Amini S, Catalano P. Am J Obstet Gynecol 2004; 191: 804-8
22 of 35 PBRC 2009
23. Conclusions
Results of the study indicated that LGA infants of mothers with
gestational diabetes mellitus have increased fat mass and decreased lean
body mass when compared with infants of mothers with normal glucose
tolerance levels.
Factors were also identified which are believed to affect the level of
fat mass an infant has.
Researchers indicated that in gestational diabetes, gestational age, and
fasting value of the oral glucose tolerance test was shown to correlate
best with the fat mass observed.
Durnwald C, Huston-Presley L, Amini S, Catalano P. Am J Obstet Gynecol 2004; 191: 804-8
23 of 35 PBRC 2009
24. Growth and Fatness at Three to Six Years of
Age of Children Born Small- or Large-for
Gestational Age
The objective of this study was to determine whether or not there are
differences in growth and fatness in early childhood as associated with
birth weight status.
Children 3 to 6 years of age who were born small-for-gestational age (SGA)
or large-for-gestational age (LGA) were compared with those who were
born appropriate-for-gestational age.
Hediger M et al. Pediatrics. 1999; 104(3).
24 of 35 PBRC 2009
25. Growth and Fatness at Three to Six Years of
Age of Children Born Small- or Large-for
Gestational Age
From the third National Health and Nutrition Examination survey, 3,192
US-born non-Hispanic white, non-Hispanic black, and Mexican-American
children were included in the study.
The children were categorized, and growth outcome was assessed by birth
weight-for-gestational age status.
The growth outcomes considered in these analyses were body weight (kg),
height (cm), head circumference (cm), mid-upper arm circumference
(MUAC; cm), and triceps and subscapular skinfold thicknesses (mm).
Hediger M et al. Pediatrics. 1999; 104(3).
25 of 35 PBRC 2009
26. Growth and Fatness at Three to Six Years of
Age of Children Born Small- or Large-for
Gestational Age
The study found that SGA children remain significantly shorter and
lighter throughout early childhood.
The children do not seem to catch up from 36 to 83 months of age.
On the other hand, LGA infants remain longer and heavier throughout
83 months of age, but, unlike children born SGA, LGA children have a
tendency to accumulate fat in early childhood.
This indicates that early childhood may be a particularly sensitive period in
which there are increases in variation in levels of fatness associated with
size at birth. If this is so, then one could conclude that intrauterine
growth is associated with size in early childhood.
Hediger M et al. Pediatrics. 1999; 104(3).
26 of 35 PBRC 2009
27. Conclusions
Further research is needed to confirm that LGA children may be at risk
for accumulating excess fat at an early age.
This study suggests that birth weight status and gestational age may be
useful in assembling a prognostic risk profile for children, with LGA infants
being placed in a category of “highest risk.”
Hediger M et al. Pediatrics. 1999; 104(3).
27 of 35 PBRC 2009
28. Maternal and Fetal Outcomes if Gestational
Impaired Glucose Tolerance is Not Treated
The purpose of this study was to evaluate whether there is increased
maternal or neonatal morbidity in connection with impaired glucose
tolerance (IGT) during pregnancy when the condition is not treated.
The 213 study participants were from a defined geographic area in
Sweden, and the study period was from 1997-2001.
Ostlund I et al. Diabetes Care. 2003; 26(7): 2107-2111.
28 of 35 PBRC 2009
29. Maternal and Fetal Outcomes if Gestational
Impaired Glucose Tolerance is Not Treated
The diagnostic criteria for gestational diabetes in this area was
limited to the criteria used for diabetes.
Because of this, 213 women, who were identified with IGT during
pregnancy, were not diagnosed or treated.
Researchers collected the data on the maternal and fetal outcomes
for each subject.
For each research subject used in the study, four control subjects
were taken from the same delivery department.
Ostlund I et al. Diabetes Care. 2003; 26(7): 2107-2111.
29 of 35 PBRC 2009
30. Maternal and Fetal Outcomes if Gestational
Impaired Glucose Tolerance is Not Treated
The researchers found that the proportion of women who underwent
cesarean section was significantly higher in the research subjects than in
the control subjects and was independently associated with IGT.
They also found that the proportion of infants who were LGA was
independently and significantly associated with untreated IGT
during pregnancy.
Admission to a neonatal intensive care unit for 2 days or longer was also
more common for infants of mothers with untreated IGT during pregnancy.
Overall, 71.3% of the children in the IGT group and 87.3% of the children
in the control group had no neonatal complications.
Ostlund I et al. Diabetes Care. 2003; 26(7): 2107-2111.
30 of 35 PBRC 2009
31. Conclusions
The researchers concluded that there is an increased independent
association between cesarean section rate, prematurity, LGA, and
macrosomic infants born to mothers with untreated IGT.
Although most of the children were healthy in this study, there was
still increased morbidity in the group of children born to mothers with
untreated IGT.
Researchers call for further investigations on this topic.
Ostlund I et al. Diabetes Care. 2003; 26(7): 2107-2111.
31 of 35 PBRC 2009
32. Heli J Roy, PhD, MBA, RD
Division of Education
Phillip Brantley, PhD, Director
Pennington Biomedical Research Center
Steven Heymfield, MD, Executive Director.
33. About Our Company
Pennington Biomedical Research Center
VISION
Our vision is to lead the world in eliminating chronic diseases.
MISSION
Our mission is to discover the triggers of chronic diseases through innovative research that improves human health across the lifespan. We are
helping people live Well Beyond the Expected.
The Pennington Center has several research areas, including:
Clinical Obesity Research
Experimental Obesity
Functional Foods
Health and Performance Enhancement
Nutrition and Chronic Diseases
Nutrition and the Brain
Dementia, Alzheimer’s and healthy aging
Diet, exercise, weight loss and weight loss maintenance
The research fostered in these areas can have a profound impact on healthy living and on the prevention of common chronic diseases, such as
heart disease, cancer, diabetes, hypertension and osteoporosis.
The Division of Education provides education and information to the scientific community and the public about research findings, training programs
and research areas, and coordinates educational events for the public on various health issues.
We invite people of all ages and backgrounds to participate in the exciting research studies being conducted at the Pennington Center in Baton
Rouge, Louisiana. If you would like to take part, visit the clinical trials web page at www.pbrc.edu or call (225) 763-3000.
33 of 35 PBRC 2009
34. References
Wong S, Oats J, Chan F, McIntyre D. Fetal growth spurt and pre-gestational
diabetic pregnancy. Diabetes Care. 2002; 25: 1681-1684.
Crowther C, Hiller J, Moss J, McPhee A, Jeffries W, Robinson J. Effect of
treatment of gestational diabetes mellitus on pregnancy outcomes. NEJM.
2005; 352(24): 2477-2486.
Schaefer-Graf U et al. Determinants of fetal growth at different periods of
pregnancies complicated by gestational diabetes mellitus or impaired glucose
tolerance. Diabetes Care. 2003; 26: 193-198.
Mello G et al. What degree of maternal metabolic control in women with type 1
diabetes is associated with normal body size and proportions in full-term
infants? Diabetes Care. 2000; 23: 1494-1498.
34 of 35 PBRC 2009
35. References
Durnwald C, Huston-Presley L, Amini S, Catalano P. Evaluation of body
composition of large-for-gestational age infants of women with gestational
diabetes mellitus compared with women with normal glucose tolerance
levels. American Journal of Obstetrics and Gynecology. 2004; 191: 804-8.
Hediger M et al. Growth and fatness at three to six years of age of
children born small- or large-for-gestational age. Pediatrics. 1999; 104(3).
Ostlund I et al. Maternal and fetal outcomes if gestational impaired
glucose tolerance is not treated. Diabetes Care. 2003; 26(7): 2107-2111.
http://www.umm.edu/ency/article/002248.htm
Copyright 2009
PBRC # PPT30 PBRC 2009
35 of 35
Notas do Editor
GDM affects 2 to 9 percent of all pregnancies and is associated with substantial rates of maternal and perinatal complications. Long-term adverse health outcomes reported among infants born to mothers with gestational diabetes include: Sustained impairment of glucose tolerance Subsequent obesity Impaired intellectual achievement The risk of perinatal mortality is not increased but the risk of macrosomia is.
The development of GDM has been shown to be directly related to increased maternal body mass index (BMI). The Nurse’s Health Study investigators found that a pre-pregnancy BMI of 30 kg/m 2 or higher was a strong risk factor for the development of GDM. Other studies have indicated that maternal obesity combined with an excessive weight gain during pregnancy are major risk factors for: pre-eclampsia, Cesarean section, preterm delivery, fetal macrosomia, and fetal death.
Macrosomia is the term used to describe an oversized fetus; the most common cause of macrosomia is maternal diabetes. Macrosomia occurs in a significant proportion of fetuses of pregnant women with diabetes, despite relatively good glycemic control. Macrosomia can lead to trauma during birth and a greater chance of a cesarean delivery. With the introduction of modern obstetric care, the incidence of congenital malformations in babies born to mothers with diabetes has reduced, but large-for-gestational age (LGA) babies and associated complications still remain high.
If the fetus or infant is larger than expected for the same age and gender, or has a birth weight above the 90th percentile, he is referred to as LGA (large for gestational age). The measurement is calculated based on the estimated gestational age of the fetus or infant in comparison to what is considered normal height, weight, head size, and developmental level for a child of the same age and gender.
In Europe and North America, there is an increasing proportion of infants born with a high birth weight. In the mid 1970s, Swedish infants more than 4 kg in weight accounted for 17% of births. By the beginning of the 1990s, this rose to 20%. A similar pattern of increased numbers of large for gestational age (LGA) and high birth weight infants (> 8 ½ lbs) occurs in North America and Europe. Researchers have found that increasing maternal weight, gestational weight gain, gestational diabetes, and reduced smoking prevalence among pregnant women may likely explain the temporal increase in proportion of LGA births between 1976 and 1996 in Canada.
The likelihood of having a LGA/macrosomic baby is related to the level of glycemic control that the mother achieves. Other maternal factors are believed to contribute to the development of LGA neonates such as: Obesity of the mother Excessive weight gain in pregnancy